Exciting technology opens the door to new treatments for cancer and infectious diseases
Posted: 1 December 2023 Burnet Institute has entered into a Research Licence and Option Agreement with biopharma company argenx for a ground-breaking technology able to transform the way we approach cancer, inflammation and infectious disease treatment. Stellabody® is simple…
Cracking the code: researchers unravel how mutant protein drives cancer growth
Posted: 29 November 2023 WEHI researchers have solved a mystery about the most important driver of cancer development – a mutant protein found in half of all cancers – and how it contributes to tumour growth. The p53…
Platform Expansion: Lung Cancer Diagnostic Test Update
Posted: 29 November 2023 Rhythm Biosciences Ltd is pleased to provide an update on its cancer diagnostics technology platform expansion program in lung cancer. As previously announced, together with the Baker Institute, Rhythm has identified a 5 biomarker…
Japan’s Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Posted: 29 November 2023 Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18…
Nuts may enhance fertility for men: study
Posted: 29 November 2023 Eating nuts may enhance male fertility, a Monash University-led research review has found. The authors now want more research into the potential benefits of nuts for male and female fertility after finding only two intervention…
2023 BioMelbourne Network AGM wrap
Posted: 24 November 2023 On Thursday 23 November, KPMG hosted 107 BioMelbourne Network members in person at the 2023 BioMelbourne Network Annual General Meeting, in Docklands. At the event, David Herd, the Board Chair, and Jeff Malone,…
First Patients Enrolled at SENTA Partners in the US
Posted: 23 November 2023 Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, confirms the first patients have been enrolled and remote patient monitoring underway as part…
Unlocking the power of the immune system to kill prostate cancer
Posted: 23 November 2023 The Albanese Government is providing $5 million to Professor Gail Risbridger and a team from Monash University, as a grant from the National Health and Medical Research Council (NHMRC) to develop CAR T cell…
Potential new treatment for prostate cancer receives $5M funding boost
Posted: 23 November 2023 A newly funded Monash University-led research program will investigate the potential of Chimeric Antigen Receptor T (CAR T) cell therapy, previously only effective in blood cancers, for the treatment of prostate cancer. Prostate cancer…
Unlocking the power of genomics with $66 million for research
Posted: 23 November 2023 The Albanese Government is unlocking the power and potential of personalised medicine with $66 million for genomics research into a number of serious diseases and common chronic conditions. The Albanese Government is unlocking the…
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Posted: 23 November 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four…
New Report: Actions Needed to Step Up Fight Against Superbug Pandemic Detailed
Posted: 22 November 2023 A new report from MTPConnect and its Australian Antimicrobial Resistance Network (AAMRNet) highlights the threat to human health posed by the rise of drug-resistant infections and presents recommendations that will equip the Australian healthcare…
